Abstracts tagged "prognostic factors"

Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima¹, Yuichi Takahashi⁸, Seiyo Honda⁹, Yoshiro Horai², Tomohiro Koga¹⁰, Mami Tamai¹¹, Kiyoshi Aoyagi¹², Ryu Watanabe⁵, Hiroshi Okuno¹³ and Katsumi Eguchi¹⁴, ¹Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Yu Family Clinic, Sendai, Japan, ⁹Kurume University School of Medicene, Kurume, Japan, ¹⁰Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ¹²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³Tohoku University Hospital, Sendai, Japan, ¹⁴Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
Abstract Number: 878 • 2013 ACR/ARHP Annual Meeting
Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis
Anne Sofie Siebuhr¹, Anne C. Bay-Jensen¹, Diana J. Leeming², Adam Platt³, Inger Byrjalsen⁴, Claus Christiansen⁵, Désirée van de Heijde⁶ and Morten Asser Karsdal², ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁶Department of Rheumatology, Leiden Univerisity, Leiden, Netherlands
Background/Purpose: As biological treatments for rheumatoid arthritis (RA) are only effective in a subpopulation of patients and the treatment can have serious side effects, there…
Abstract Number: 695 • 2013 ACR/ARHP Annual Meeting
Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis
Nicolas Champtiaux¹, Vincent Cottin², Eric Hachulla³, Dominique Valeyre⁴, Hilario Nunes⁵, David Launay⁶, Alice Berezne⁷, Bruno Crestani⁸, Loic Guillevin⁹, Jean-Francois Cordier² and Luc Mouthon¹⁰, ¹Service de Médecine Interne, hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ³Internal Medicine, Lille CEDEX, France, ⁴Department of Pneumology, Avicenne hospital (APHP), Bobigny, France, ⁵Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁷Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁸Pneumology A, Hôpital Bichat, Paris, France, ⁹Internal Medicine, Cochin University Hospital, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis Background/Purpose: Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or…
Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Kwi Young Kang¹, Chan Hong Jeon², Sung Jae Choi³, Seung-Ki Kwok⁴, Seong-Kyu Kim⁵, Hyoun-Ah Kim⁶, Eon Jeong Nam⁷, Yong-Beom Park⁸, Kichul Shin⁹, Jaejoon Lee¹⁰, Chang-Hoon Lee¹¹, Chan-Bum Choi¹², Shin-Seok Lee¹³ and Dae-Hyun Yoo¹⁴, ¹Rheumatology, Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Seoul, South Korea, ²Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ³Rheumatology, Korea University Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁷Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁹Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, ¹⁰Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹¹Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ¹³Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ¹⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…
Abstract Number: 2896 • 2013 ACR/ARHP Annual Meeting
Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce¹, Aidan O'Keefe², Li Su³, Vernon Farewell⁴, John G. Hanly⁵, Susan Manzi⁶, Murray B. Urowitz⁷ and Systemic Lupus International Collaborating Clinics (SLICC)⁸, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Cambridge, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁵Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Irreversible damage is an important outcome in patients with SLE. We aimed to study damage accrual in early SLE. We examined the rate of…
Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Nevsun Inanc^1,2, Gülsen Ozen² and Haner Direskeneli³, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…
Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Amir Haddad¹, Arane Thavaneswaran¹, Ioana Ruiz Arruza², Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…
Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Chisa Okura¹, Yukio Yonemoto², Koichi Okamura¹, Tetsuya Kaneko³, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
Abstract Number: 2335 • 2013 ACR/ARHP Annual Meeting
Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy
Heikki Valleala¹, Markku Korpela², Markku J. Kauppi³ and Yrjo T. Konttinen⁴, ¹Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ²Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴Dept of Medicine, Helsinki Univ Central Hospital, Helsinki, Finland
Background/Purpose: Autoreactive B-cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the aetiology of various human chronic autoimmune diseases. The aim of…
Abstract Number: 2260 • 2013 ACR/ARHP Annual Meeting
Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis
Bjorn Svensson¹, Ingiäld Hafström², Malin Erlandsson³, Kristina Forslind⁴ and Maria Bokarewa³, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden
Background/Purpose: High levels of the oncoprotein survivin may be detected in the majority of patients with early rheumatoid arthritis (RA). Survivin is a sensitive predictor…
Abstract Number: 2140 • 2012 ACR/ARHP Annual Meeting
A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study
Paul Bird¹, David Nicholls², Julien P. de Jager³, Hedley Griffiths⁴, Lynden Roberts⁵, Kathleen Tymms⁶, Jane Zochling⁷, Mark H. Arnold⁸, Geoffrey O. Littlejohn⁹ and OPAL Consortium¹⁰, ¹Combined Rheumatology Practice, Sydney, Australia, ²Coast Joint Care, Maroochydore, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Barwon Rheumatology Service, Geelong, Australia, ⁵School of Medicine, James Cook University, Townsville, Australia, ⁶Canberra Rheumatology, Canberra, ACT, Australia, ⁷Menzies Research Institute Tasmania, Hobart, Australia, ⁸Orthopaedic Arthritis Spec Ctr, Level 2 The Gallery, Chatswood, Australia, ⁹Rheumatology, Monash Medical Center, Melbourne, Australia, ¹⁰Melbourne, Australia
Background/Purpose: Despite the conspicuous increase in available treatment for rheumatoid arthritis [RA], and the shift to early, more aggressive management, there is a paucity of…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 1189 • 2012 ACR/ARHP Annual Meeting
Stromal Cell Markers in the Synovial Tissue of Patients with Early Arthritis and Preclinical Rheumatoid Arthritis
Yuen Kei Choi¹, Olga N. Karpus², Paul Peter Tak³, Jörg Hamann⁴, Christopher D. Buckley⁵, Andrew Filer⁶ and Danielle M. Gerlag⁷, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²1Departments of Experimental Immunology and Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Center for Translational Inflammation Research, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, ⁶Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Stromal cells in synovial tissue (ST) of patients with arthritis may have an important role in the initiation and persistence of the inflammatory infiltrate.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].